Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
13%(1 trials)

Phase Distribution

Ph not_applicable
3
23%
Ph phase_1
3
23%
Ph phase_2
6
46%
Ph phase_4
1
8%

Phase Distribution

3

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
3(23.1%)
Phase 2Efficacy & side effects
6(46.2%)
Phase 4Post-market surveillance
1(7.7%)
N/ANon-phased studies
3(23.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(8)
Terminated(1)
Other(4)

Detailed Status

Completed8
unknown4
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (23.1%)
Phase 26 (46.2%)
Phase 41 (7.7%)
N/A3 (23.1%)

Trials by Status

withdrawn18%
unknown431%
completed862%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_2

Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia

NCT06924749
completedphase_1

Study of Epigallocatechin-3-gallate (EGCG) for Supportive and Symptomatic Management in Patients With Esophageal Cancer

NCT05039983
completednot_applicable

Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal Intervention

NCT03978052
unknownphase_1

Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients

NCT05758571
withdrawnphase_2

Effect of EGCG on the Body's Response to Insulin

NCT00434499
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT06924749Phase 2

Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia

Completed
NCT05039983Phase 1

Study of Epigallocatechin-3-gallate (EGCG) for Supportive and Symptomatic Management in Patients With Esophageal Cancer

Completed
NCT03978052Not Applicable

Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal Intervention

Completed
NCT05758571Phase 1

Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients

Unknown
NCT00434499Phase 2

Effect of EGCG on the Body's Response to Insulin

Withdrawn
NCT01481818Phase 1

Study of Topically Applied Green Tea Extract for Radio Dermatitis and Radiation Mucositis

Unknown
NCT02577393Phase 2

Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy

Unknown
NCT01855971Phase 2

"Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome" (TESFX)

Completed
NCT02580279Phase 2

Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy

Unknown
NCT02731495Phase 2

Effect of Epigallocatechin -3-gallate Supplementation in Traumatic Brain Injury Patients

Completed
NCT01662232Not Applicable

Improvement of Endothelial Function by EGCG

Completed
NCT00981292Phase 4

Effects of Epigallocatechin Gallate (EGCG) in Healthy, Young Adults

Completed
NCT00611416Not Applicable

The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism

Completed

All 13 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
13